KR20130108295A - 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 - Google Patents

항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 Download PDF

Info

Publication number
KR20130108295A
KR20130108295A KR1020137006354A KR20137006354A KR20130108295A KR 20130108295 A KR20130108295 A KR 20130108295A KR 1020137006354 A KR1020137006354 A KR 1020137006354A KR 20137006354 A KR20137006354 A KR 20137006354A KR 20130108295 A KR20130108295 A KR 20130108295A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137006354A
Other languages
English (en)
Korean (ko)
Inventor
제라드 주라브스키
에프. 반슈로 자크
안-로르 플라마르
Original Assignee
베일러 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베일러 리서치 인스티튜트 filed Critical 베일러 리서치 인스티튜트
Publication of KR20130108295A publication Critical patent/KR20130108295A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/106Vibrio; Campylobacter; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020137006354A 2010-08-13 2011-08-12 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 Withdrawn KR20130108295A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37376310P 2010-08-13 2010-08-13
US61/373,763 2010-08-13
PCT/US2011/047633 WO2012021834A1 (en) 2010-08-13 2011-08-12 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Publications (1)

Publication Number Publication Date
KR20130108295A true KR20130108295A (ko) 2013-10-02

Family

ID=45564978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137006354A Withdrawn KR20130108295A (ko) 2010-08-13 2011-08-12 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제

Country Status (14)

Country Link
US (1) US20120039916A1 (enExample)
EP (1) EP2603235A4 (enExample)
JP (1) JP2013535508A (enExample)
KR (1) KR20130108295A (enExample)
CN (1) CN103328005A (enExample)
AR (1) AR082686A1 (enExample)
AU (1) AU2011289234B2 (enExample)
BR (1) BR112013002940A2 (enExample)
CA (1) CA2807585A1 (enExample)
MX (1) MX2013001527A (enExample)
RU (1) RU2013110889A (enExample)
TW (1) TWI506035B (enExample)
WO (1) WO2012021834A1 (enExample)
ZA (1) ZA201301013B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240112401A (ko) * 2023-01-11 2024-07-19 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
CN101820910B (zh) * 2007-05-03 2014-08-06 新加坡科技研究局 结合细胞内prl-1多肽或prl-3多肽的抗体
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
US9045542B2 (en) 2011-08-29 2015-06-02 Baylor Research Institute Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)
EP2822599A4 (en) * 2012-03-05 2015-12-23 Univ Duke VACCINE FORMULATION
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
EP3013362B1 (en) 2013-06-28 2021-08-04 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US10202450B2 (en) 2013-09-05 2019-02-12 Duke University Nav 1.7 antibodies and methods of using the same
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
US20160340439A1 (en) * 2014-01-22 2016-11-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
WO2015187637A1 (en) * 2014-06-02 2015-12-10 Baylor Research Institute Methods and compositions for treating allergy and inflammatory diseases
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN104689313A (zh) * 2015-03-04 2015-06-10 中国科学院海洋研究所 大菱鲆cd83分子作为疫苗佐剂的应用
US10624964B2 (en) 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CA3002095A1 (en) * 2015-11-10 2017-05-18 Yale University Compositions and methods for treating autoimmune diseases and cancers
EP3389707B1 (en) 2015-12-15 2025-08-20 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunogenic construct comprising an ebv-cell antigen and a targeting moiety and applications thereof
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
WO2019006038A1 (en) * 2017-06-28 2019-01-03 The Board Of Trustees Of The Leland Stanford Junior University METHODS AND COMPOSITIONS FOR STIMULATING DECTINE 2 AND CANCER IMMUNOTHERAPY
US20210369635A1 (en) * 2017-11-29 2021-12-02 Adaptive Phage Therapeutics, Inc. Novel methods of vaccination using icosahedral phage
WO2019166432A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
US20220106566A1 (en) * 2019-01-22 2022-04-07 The Brigham And Women`S Hospital, Inc. Antigen-Presenting Neutrophil-Derived Dendritic Cells and Methods of Use Thereof
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
US20220298255A1 (en) * 2019-05-31 2022-09-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
CN114787181A (zh) * 2019-11-21 2022-07-22 Inserm(法国国家健康医学研究院) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023525140A (ja) 2020-05-13 2023-06-14 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) Ox40活性化特性を有する組換えタンパク質
JP2023528017A (ja) 2020-05-26 2023-07-03 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
CN111850006B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用
KR20230107260A (ko) 2020-11-12 2023-07-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
US11572407B2 (en) * 2020-11-18 2023-02-07 Pionyr Immunotherapeutics, Inc. Anti-MARCO antibodies and uses thereof
CA3205280A1 (en) 2020-12-23 2022-06-30 Inserm (Institut National De La Sante Et De La Recherche Medicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
MX2023008986A (es) 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
CN118555970A (zh) * 2021-11-04 2024-08-27 总医院有限公司 抗间皮素抗体试剂
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
EP4601682A1 (en) * 2022-10-13 2025-08-20 The Brigham & Women's Hospital, Inc. Methods and compositions for improving response to immunotherapy
WO2024216189A1 (en) * 2023-04-13 2024-10-17 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057915C (zh) * 1994-09-19 2000-11-01 中国医学科学院医药生物技术研究所 免疫佐剂
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
BRPI0807160A2 (pt) * 2007-02-02 2018-09-25 Baylor Res Institute vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno
TWI423985B (zh) * 2007-02-23 2014-01-21 Baylor Res Inst 利用dectin-1活化人類抗原呈現細胞之醫療應用
BRPI0820270A2 (pt) * 2007-11-07 2015-06-16 Celldex Therapeutics Inc Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
ES2685823T3 (es) * 2008-07-16 2018-10-11 Baylor Research Institute Anticuerpos antagonistas anti-CD40
JP2012520073A (ja) * 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗原提示細胞ターゲティングワクチン
CN105837691B (zh) * 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
EP2406286B1 (en) * 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
US20110274653A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240112401A (ko) * 2023-01-11 2024-07-19 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CA2807585A1 (en) 2012-02-16
US20120039916A1 (en) 2012-02-16
JP2013535508A (ja) 2013-09-12
BR112013002940A2 (pt) 2019-09-24
AR082686A1 (es) 2012-12-26
RU2013110889A (ru) 2014-09-20
EP2603235A4 (en) 2014-04-09
EP2603235A1 (en) 2013-06-19
ZA201301013B (en) 2015-10-28
WO2012021834A1 (en) 2012-02-16
CN103328005A (zh) 2013-09-25
AU2011289234A1 (en) 2013-02-21
TWI506035B (zh) 2015-11-01
TW201208696A (en) 2012-03-01
AU2011289234B2 (en) 2014-09-11
MX2013001527A (es) 2013-04-24

Similar Documents

Publication Publication Date Title
KR20130108295A (ko) 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
TW201247706A (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
KR102806206B1 (ko) 저-점도 항원 결합 단백질 및 이의 제조 방법
KR102890653B1 (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
DK2519543T3 (en) HETERODIMER BINDING PROTEINS AND USE THEREOF
KR102182485B1 (ko) 단백질 약물의 불활성화를 위한 항체 로커
AU2015292406B2 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
KR101963923B1 (ko) 이중특이적 t 세포 활성화 항원 결합 분자
TWI289668B (en) Therapeutic human anti-IL-1R1 monoclonal antibody
KR101901458B1 (ko) Tcr 복합체 면역치료제
KR20180099723A (ko) 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도
KR20180081532A (ko) 암 치료용 조성물 및 방법
KR20150122761A (ko) T 세포 활성화 항원 결합 분자
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
CN107056951A (zh) Cd86拮抗物多靶点结合蛋白
TW201217397A (en) Antibodies to MAdCAM
CN111954680A (zh) IL2Rβ/共同γ链抗体
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
CN107949575A (zh) Cys80缀合型免疫球蛋白
TW202216743A (zh) Il-10突變蛋白及其融合蛋白
CN114502151B (zh) 抗cd19抗体及其使用和制备方法
RU2834996C1 (ru) Антитела против cd19 и способы их применения и получения
RU2838544C1 (ru) МИНИАТЮРНЫЕ АНТИТЕЛОПОДОБНЫЕ БЕЛКИ УПРАВЛЕНИЯ И НАВИГАЦИОННОГО КОНТРОЛЯ (miniGNC) И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
HK40065811B (zh) 抗cd19抗体及其使用和制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid